Phase 2 and Pre-clinical/Phase 1 companies with lead drug candidates targeting oncology lead aggregate funding in the space.
Speaking of healthcare, in our first client-only market map last week, we looked at how far along 100+ of the most well-funded pharma startups were in their clinical trial pipelines, as well as the diseases targeted by their leading drug candidates. Oncology was by far the most common target among the group.
Here we take a closer look at how much money has been raised by companies sorted by clinical trial phase + drug indication. Phase 2 and Pre-clinical/Phase 1 companies with lead drug candidates targeting oncology are ranked #1 and #2, respectively, for aggregate funding.